1. Patient ‐reported pain results.

Study ID	Pain scale	Baseline mean	End of study mean	% improvement, mean	Mean change from baseline	Variance (P value or CI)
Moreland 2002 ‐ abatacept; 85 days	1‐5	3.47	2.43	28.1	‐	NR
Moreland 2002 ‐ placebo; 85 days	1‐5	3.55	3.24	4.6	‐	NR
Kremer 2003 ‐ abatacept; 6 months	100mm VAS	NR	NR	‐	‐46.4	P < 0.05 (between groups)
Kremer 2003 ‐ placebo; 6 months	100mm VAS	NR	NR	‐	‐8.4	‐
Weinblatt 2006 ‐ abatacept; 1 yr	VAS	NR	NR	‐	‐26.3	P < 0.001 (within group)
Weinblatt 2006 ‐ placebo; 1 yr	VAS	NR	NR	‐	‐16.4	P < 0.001 (within group)
Weinblatt 2007 ‐ abatacept; 1 yr	NR	65.5	43.6	33.4	‐22.0	P < 0.001 (within group)
Weinblatt 2007 ‐ placebo; 1 yr	NR	53.2	47.4	10.9	‐7.1	P < 0.001 (within group)
Kremer 2006 ‐ abatacept; 1 yr	100mm VAS	NR	NR	‐	‐35.8	‐12.6 95% CI (‐16.9 to ‐8.39)
Kremer 2006 ‐ placebo; 1 yr	100mm VAS	NR	NR	‐	‐23.2

NR = not reported

VAS = visual analogue scale

*calculated as the average of the changes in the individual patient data